MAP2K7 and melanoma: Currently, BRAFV600E-selective inhibitors (BRAFis), such as dabrafenib, encorafenib, and vemurafenib, and MEK inhibitors (MEKis) including binimetinib, cobimetinib, and trametinib, have been approved by the US FDA for the treatment of melanoma [213].